-
Information-Publications
-
Napabucasin attenuates resistance of breast cancer cells to tamoxifen by reducing stem cell-like propertiesDetails
-
Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutationDetails
-
Molecular identification of peptidoglycan recognition protein 5 and its functional characterization in innate immunity of large yellow croaker, Larimichthys croceaDetails
-
Construction of an ATP-Activated Y-Shape DNA Probe for Smart miRNA Imaging in Living CellsDetails
-
Oncogenic EFNA4 amplification promotes lung adenocarcinoma lymph node metastasisDetails
-
Construction and functional verification of size-reduced plasmids based on TMP resistance gene dfrB10Details
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands